Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology
Biomedical Chromatography · 2026-09 · 40 (9)
DOI: 10.1002/bmc.70592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 10.08.2026. Verfasst von Nishmitha R Poojary und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. Hauptthemen laut MEDLINE: Vitex, Metabolomics, Polycystic Ovary Syndrome, Metabolome. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manipal Academy of Higher Education, Manipal, India, Manipal Academy of Higher Education.
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is a hormonal disorder marked by irregular menstrual cycles, elevated androgen levels, ovarian cysts, hirsutism, acne and other symptoms. While conventional medications such as Metformin and Spironolactone are commonly prescribed, they are often associated with undesirable side effects. As a result, there is growing interest in alternative treatments, particularly those involving medicinal plants. Vitex negundo L., a member of the Lamiaceae family, has demonstrated promising therapeutic effects against PCOS. However, its precise molecular mechanism of action remains unclear. To explore this, we conducted an untargeted metabolomics analysis using UPLC‐MS/MS to identify bioactive compounds, followed by network pharmacology to elucidate potential mechanisms. Metabolite fingerprinting revealed 186 metabolites, among which 122 were identified as secondary metabolites. Network pharmacology analysis uncovered 910 potential targets associated with the identified compounds and 297 known PCOS‐related disease targets, with 50 overlapping targets between the two datasets. Key hub targets identified included P53, ESR1, AKT1, STAT3, CTNNB1, ERBB2, BCL2, EGFR, MTOR and IL6. Furthermore, molecular docking highlighted several bioactive constituents—syringin, 4‐(3,4‐dihydroxyphenyl)‐6,7‐dihydroxynaphthalene‐2‐carboxylic acid, and Isovitexin—as potential lead compounds for PCOS treatment. Further evaluation of lead compounds can be conducted through in vitro and in vivo studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
ORCID-Profile: Padmalatha S Rai
Förderung
- Manipal Academy of Higher Education, Manipal, India
- Manipal Academy of Higher Education
Zitieren
APA
Poojary, N. R., Venkatasai, N. N., Sanjay, K. U., Kodanch, S. M., & Rai, P. S. (2026). Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology. Biomedical Chromatography, 40(9). https://doi.org/10.1002/bmc.70592
Vancouver
Poojary NR, Venkatasai NN, Sanjay KU, Kodanch SM, Rai PS. Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology. Biomedical Chromatography. 2026;40(9). doi:10.1002/bmc.70592
BibTeX
@article{Poojary2026,
author = {Poojary, Nishmitha R and Venkatasai, Neeharika Narisepalli and Sanjay, Kannath U and Kodanch, Supraja M and Rai, Padmalatha S},
title = {Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {9},
doi = {10.1002/bmc.70592}
}
EUVIMED